Current Concepts and Controversies in Neurodegeneration with Brain Iron Accumulation

Seminars in Pediatric Neurology

Volumn 19, Issue 2, 2012, Pages 51-56

  Keogh, Michael J ^a   Chinnery, Patrick F ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; CERULOPLASMIN; DEFERIPRONE; IRON; TRIHEXYPHENIDYL;

ATP13A2 GENE; AUTOSOMAL DOMINANT DISORDER; C19ORF12 GENE; CERULOPLASMIN GENE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSTONIA; FA2H GENE; FERRITIN LIGHT CHAIN GENE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IRON METABOLISM; IRON OVERLOAD; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; NEUROAXONAL DYSTROPHY; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; NEUROIMAGING; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PKAN2 GENE; PLA2G6 GENE; REVIEW; SEQUENCE ANALYSIS; SPASTICITY;

ANIMALS; BRAIN; HUMANS; IRON; IRON METABOLISM DISORDERS; NEUROAXONAL DYSTROPHIES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 84862321330     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2012.03.004     Document Type: Review

References (50)

1. Gregory A., Hayflick S. Pantothenate kinase-associated neurodegeneration. GeneReviews [Internet] 2010, Updated. Seattle, WA. R.A. Pagon, T.C. Bird, C.R. Dolan (Eds.).
2. Morgan N.V., Westaway S.K., Morton J.E., et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006, 38:752-754.
3. Paisan-Ruiz C., Bhatia K.P., Li A., et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009, 65:19-23.
4. Curtis A.R., Fey C., Morris C.M., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001, 28:350-354.
5. Grisoli M., Piperno A., Chiapparini L., et al. MR imaging of cerebral cortical involvement in aceruloplasminemia. Am J Neuroradiol 2005, 26:657-661.
6. Kruer M.C., Paisán-Ruiz C., Boddaert N., et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010, 68:611-618.
7. Schneider S.A., Paisan-Ruiz C., Quinn N.P., et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010, 25:979-984.
8. Hartig M.B., Iuso A., Haack T., et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 2011, 89:543-550.
9. Gregory A., Polster B.J., Hayflick S.J. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009, 46:73-80.
10. Hayflick S.J., Westaway S.K., Levinson B., et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003, 348:33-40.
11. Aggarwal A., Schneider S.A., Houlden H., et al. Indian-subcontinent NBIA: Unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms. Mov Disord 2010, 25:1424-1431.
12. Antonini A., Goldwurm S., Benti R., et al. Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. Mov Disord 2006, 21:417-418.
13. Schneider S.A., Hardy J., Bhatia K.P. Syndromes of neurodegeneration with brain iron accumulation (NBIA): An update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord 2012, 27:42-53.
14. Chinnery P.F., Crompton D.E., Birchall D., et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007, 130:110-119.
15. Cassidy AJ, Williams ER, Goldsmith P, et al: The man who could not walk backward: An unusual presentation of neuroferritinopathy. Mov Disord 26:362-364.
16. Dick KJ, Eckhardt M, Paisán-Ruiz C, et al: Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum Mutat 31:E1251-E1260.
17. Edvardson S., Hama H., Shaag A., et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am J Hum Genet 2008, 83:643-648.
18. * and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008, 70:1614-1619.
19. Sethi K.D., Adams R.J., Loring D.W., et al. Hallervorden-Spatz syndrome: Clinical and magnetic resonance imaging correlations. Ann Neurol 1988, 24:692-694.
20. Davie C.A., Barker G.J., Machado C., et al. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 1997, 12:767-771.
21. Kumar N., Boes C.J., Babovic-Vuksanovic D., et al. The "eye-of-the-tiger" sign is not pathognomonic of the PANK2 mutation. Arch Neurol 2006, 63:292-293.
22. Molinuevo J.L., Muñoz E., Valldeoriola F., et al. The eye of the tiger sign in cortical-basal ganglionic degeneration. Mov Disord 1999, 14:169-171.
23. Hourani R., El-Hajj T., Barada W.H., et al. MR imaging findings in autosomal recessive hereditary spastic paraplegia. AJNR Am J Neuroradiol 2009, 30:936-940.
24. Chien H.F., Bonifati V., Barbosa E.R. ATP13A2-related neurodegeneration (PARK9) without evidence of brain iron accumulation. Mov Disord 2011, 26:1364-1365.
25. * relaxation rate. Am J Neuroradiol (in press).
26. Zorzi G., Zibordi F., Chiapparini L., et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. Mov Disord 2011, 26:1756-1759.
27. MacDonald M. Ironing out neurodegeneration: Mutations in a phospholipase A2 cause neurodegenerative diseases with iron accumulation. Clin Genet 2006, 70:306-311.
28. Schneider S.A., Hardy J., Bhatia K.P. Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2: Causative or consequential?. J Neurol Neurosurg, Psychiatry 2009, 80:589-590.
29. Horvarth R, Holinski-Feder E, Neeve VCM, et al: A new phenotype of brain iron accumulation with dystonia, optic atrophy and peripheral neuropathy. Mov Disord (in press).
30. Panteghini C., Zorzi G., Venco P., et al. C19orf12 and FA2H mutations are rare in Italian patients with neurodegeneration with brain iron accumulation. Semin Pediatr Neurol 2012, 19:75-81.
31. Yu-Wai-Man P., Sitarz K.S., Samuels D.C., et al. OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. Hum Mol Genet 2010, 19:3043-3052.
32. Stankiewicz J., Panter S.S., Neema M., et al. Iron in chronic brain disorders: Imaging and neurotherapeutic implications. Neurotherapeutics 2007, 4:371-386.
33. Sian-Hülsmann J., Mandel S., Youdim M.B., et al. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2011, 118:939-957.
34. Paisán-Ruiz C., Li A., Schneider S.A., et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2012, 33:814-823.
35. Gregory A., Westaway S.K., Holm I.E., et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008, 71:1402-1409.
36. Mak C.M., Sheng B., Lee H.H., et al. Young-onset parkinsonism in a Hong Kong Chinese man with adult-onset Hallervorden-Spatz syndrome. Int J Neurosci 2011, 121:224-227.
37. McNeill A., Pandolfo M., Kuhn J., et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008, 60:200-205.
38. Patil P.V., Manakshe G., Mahajan D.P., et al. Neurodegeneration with brain iron accumulation-Late onset slowly progressive variant. J Assoc Physicians India 2011, 59:319-321.
39. Hayflick S.J. Neurodegeneration with brain iron accumulation: From genes to pathogenesis. Semin Pediatr Neurol 2006, 13:182-185.
40. Ge M., Zhang K., Ma Y., et al. Bilateral subthalamic nucleus stimulation in the treatment of neurodegeneration with brain iron accumulation type 1. Stereotact Funct Neurosurg 2011, 89:162-166.
41. Timmermann L., Pauls K.A., Wieland K., et al. Dystonia in neurodegeneration with brain iron accumulation: Outcome of bilateral pallidal stimulation. Brain 2010, 133:701-712.
42. Abbruzzese G., Cossu G., Balocco M., et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011, 96:1708-1711.
43. Kwiatkowski A., Ryckewaert G., Jissendi Tchofo P., et al. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat Disord 2012, 18:110-112.
44. Di Prospero N.A., Baker A., Jeffries N., et al. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: A randomised, placebo-controlled trial. Lancet Neurol 2007, 6:878-886.
45. Tonon C., Lodi R. Idebenone in Friedreich's ataxia. Expert Opin Pharmacother 2008, 9:2327-2337.
46. Fogel B.L., Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol 2007, 6:245-257.
47. Velasco-Sánchez D., Aracil A., Montero R., et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011, 10:1-8.
48. Keogh M.J., Jonas P., Coulthard A., et al. Neuroferritinopathy: A new inborn error of iron metabolism. Neurogenetics 2012, 13:93-96.
49. Barbeito A.G., Garringer H.J., Baraibar M.A., et al. Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene. J Neurochem 2009, 109:1067-1078.
50. Deng X., Vidal R., Englander E.W. Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci Lett 2010, 479:44-48.